The Latest Cardiac and Vascular News
THOUSAND OAKS, Calif., Nov. 23, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. Omecamtiv mecarbil, an investigational selective cardiac myosin activator, was studied in GALACTIC-HF, […]
THOUSAND OAKS, Calif., Oct. 28, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2020. Key results include: Total revenues increased 12% to $6.4 billion in comparison to the third quarter of 2019 driven by higher volume growth, partially offset by lower net selling prices and the effects of […]
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Results Will Be Presented in Late Breaking Clinical Trial Session at AHA Scientific Sessions 2020 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Oct. 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, […]
‘Control Cholesterol’ to Support the NHS in Delivering on Long-Term Plan Ambitions and Improve Health Outcomes for Patients in the North West Coast of England Quality Management Approach Aims to Help Predict and Prevent Heart Attacks and Strokes For More Than 300,000 People With Dangerously High Cholesterol Levels CAMBRIDGE, England–(BUSINESS […]
Repatha (Evolocumab) Late-Breaking Data Showcase First Phase 3 Study of a PCSK9 Inhibitor in Pediatric Heterozygous Familial Hypercholesterolemia New Data Highlight Gaps in Treating High LDL-C to Clinical Treatment Guidelines in a Large Cohort of European, High-Risk CVD Patients THOUSAND OAKS, Calif., Aug. 25, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a Phase 2 clinical study. The study is evaluating the efficacy, safety, and tolerability […]
Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin […]
Amgen K.K. Will Focus on Bringing Amgen’s Full Global Pipeline to Japanese Patients THOUSAND OAKS, Calif., March 31, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in […]
Study Met Primary Endpoint (Change From Baseline in LDL-C) and All Secondary Endpoints Repatha is the First PCSK9 Inhibitor to Demonstrate LDL-C Lowering Results in People Living with HIV THOUSAND OAKS, Calif., March 28, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human […]
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes Topline Results Expected in Q4 2020 THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 26, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, Incorporated (NASDAQ:CYTK) and Servier today announced that the Data Monitoring Committee (DMC) […]
